Aero Therapeutics Wins $150,000

May 14th, 2021

 

New Haven, CT – Dr. Anjelica Gonzalez pitched to the full Blavatnik board on 12May2021 and was awarded $150,000.

 

Aero met with FDA back in March and received guidance on steps required for regulatory approval in the US through the Pre-Submission process. We will spend the Blavatnik funds on completing the steps needed to get PremieBreathe through FDA approval within a year's time.

 

The Path to The Blavatnik

Dr. Gonzalez previously participated in Yale University’s Lifesciences Pitchfest competition last December where she won two awards during the competition: the Audience Choice award and the Most Valuable Pitch award.

Yale Pitchfest is a yearly pitch competition for faculty innovators who are Semifinalists in the Blavatnik Fund’s grant cycle. Finalists are selected every January and awarded by May.

The Blavatnik Fund for Innovation at Yale, made possible by a generous grant from the Blavatnik Family Foundation, supports Yale faculty in the commercialization of applied research and technology in the life sciences. The Fund aims to bridge the gap between innovative, early-stage life science research and successful development of high-impact biomedical products.

 

 

Every breath matters.

Aero Therapeutics is an early-stage medical device company. Aero’s first device is a self-sterilizing high-flow respirator designed for extremely low resource settings. For more information please visit www.BreatheAero.com.

TempLogo2.png